Compare Biogen Inc (BIIB) vs iShares MSCI Canada (TSX) (EWC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs iShares MSCI Canada (TSX) — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while iShares MSCI Canada (TSX) trades at $61.82. The key difference: iShares MSCI Canada (TSX) is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | EWC | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.63 | $61.51 |
52-Week Low | $128.93 | $47.00 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
EWC trades at $61.77, up 0.44% today, with a bullish technical signal from moving averages but overbought RSI levels. The ETF shows strong 2026 performance, though trailing the S&P 500, and faces trade tensions as U.S. tariffs on Canadian goods loom, potentially impacting exports excluding energy and potash.
Outlook is mixed: growth drivers include Canada's record exports and active ETF trends, but risks from tariff escalations and political uncertainty weigh. Investors balance double-digit returns against trade war volatility, with key support at $61.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →
